gemtesa
Selected indexed studies
- Vibegron (Gemtesa) for overactive bladder. (Med Lett Drugs Ther, 2021) [PMID:33976098]
- Vibegron. (, 2006) [PMID:39836798]
- Vibegron. (, 2012) [PMID:37535798]
_Worker-drafted node — pending editorial review._
Connections
gemtesa is a side effect of
Sources
- Efficacy and safety of vibegron compared with mirabegron for overactive bladder: A systematic review and network meta-analysis. (2023) pubmed
- Vibegron (Gemtesa) for overactive bladder. (2021) pubmed
- Vibegron. (2006) pubmed
- Vibegron. (2012) pubmed
- Comparative assessment of efficacy and safety of approved oral therapies for overactive bladder: a systematic review and network meta-analysis. (2023) pubmed
- Editorial Comment. (2020) pubmed
- Efficacy and Safety of Vibegron for Persistent Symptoms of Overactive Bladder in Men Being Pharmacologically Treated for Benign Prostatic Hyperplasia: Results From the Phase 3 Randomized Controlled COURAGE Trial. (2024) pubmed
- International Phase III, Randomized, Double-Blind, Placebo and Active Controlled Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder: EMPOWUR. (2020) pubmed
- Benigne Prostatahyperplasie: Vibegron bei Drangbeschwerden effektiv und sicher. (2025) pubmed
- RAB32-Related Parkinson Disease. (1993) pubmed